NCT04696432View on ClinicalTrials.gov

A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

November 27, 2020

Primary Completion Date

July 31, 2023

Study Completion Date

December 30, 2023

Conditions
Non-Hodgkin's B-cell Lymphoma
Interventions
BIOLOGICAL

Prizloncabtagene autoleucel

Autologous 2nd generation CD19/CD20-directed CAR-T cells, single infusion intravenously

Trial Locations (1)

300060

Tianjin Medical University Cancer Institute & Hosipital, Tianjin

All Listed Sponsors
collaborator

Shanghai AbelZeta Ltd.

INDUSTRY

lead

Tianjin Medical University Cancer Institute and Hospital

OTHER

NCT04696432 - A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter